Principal Investigator
Estelamari Rodriguez
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231035
Clinical Trial Summary
LCCC 2117: Phase II Study of Trilaciclib and Lurbinectidin in Small Cell Lung Cancer
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647